228 related articles for article (PubMed ID: 24700598)
41. Vancomycin nephrotoxicity: a review.
Mergenhagen KA; Borton AR
J Pharm Pract; 2014 Dec; 27(6):545-53. PubMed ID: 25266809
[TBL] [Abstract][Full Text] [Related]
42. Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin.
Minkutė R; Briedis V; Steponavičiūtė R; Vitkauskienė A; Mačiulaitis R
J Clin Pharm Ther; 2013 Dec; 38(6):462-7. PubMed ID: 23924288
[TBL] [Abstract][Full Text] [Related]
43. [Efficacy and nephrotoxicity of vancomycin in the treatment of Gram positive infections].
Du B; Chen DC; Liu DW
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Jan; 15(1):32-4. PubMed ID: 12852813
[TBL] [Abstract][Full Text] [Related]
44. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient.
Vance-Bryan K; Rotschafer JC; Gilliland SS; Rodvold KA; Fitzgerald CM; Guay DR
J Antimicrob Chemother; 1994 Apr; 33(4):811-21. PubMed ID: 8056700
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center.
Marquis KA; DeGrado JR; Labonville S; Kubiak DW; Szumita PM
Ann Pharmacother; 2015 Sep; 49(9):1009-14. PubMed ID: 25991831
[TBL] [Abstract][Full Text] [Related]
46. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.
Kullar R; Davis SL; Taylor TN; Kaye KS; Rybak MJ
Pharmacotherapy; 2012 Mar; 32(3):195-201. PubMed ID: 22392452
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
[TBL] [Abstract][Full Text] [Related]
48. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
Pauly DJ; Musa DM; Lestico MR; Lindstrom MJ; Hetsko CM
Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556
[TBL] [Abstract][Full Text] [Related]
49. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?
Kralovicová K; Spanik S; Halko J; Netriova J; Studena-Mrazova M; Novotny J; Grausova S; Koren P; Krupova I; Demitrovicova A; Kukuckova E; Krcmery V
J Chemother; 1997 Dec; 9(6):420-6. PubMed ID: 9491842
[TBL] [Abstract][Full Text] [Related]
50. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.
Kullar R; McClellan I; Geriak M; Sakoulas G
Pharmacotherapy; 2014 Jun; 34(6):582-9. PubMed ID: 24658897
[TBL] [Abstract][Full Text] [Related]
52. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.
McKamy S; Hernandez E; Jahng M; Moriwaki T; Deveikis A; Le J
J Pediatr; 2011 Mar; 158(3):422-6. PubMed ID: 20888013
[TBL] [Abstract][Full Text] [Related]
53. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy.
Nahata MC
Chemotherapy; 1987; 33(4):302-4. PubMed ID: 3608631
[TBL] [Abstract][Full Text] [Related]
54. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Antoniou T; Raboud J; Chirhin S; Yoong D; Govan V; Gough K; Rachlis A; Loutfy M
HIV Med; 2005 Jul; 6(4):284-90. PubMed ID: 16011534
[TBL] [Abstract][Full Text] [Related]
55. Vancomycin-Associated Nephrotoxicity: The Obesity Factor.
Davies SW; Efird JT; Guidry CA; Dietch ZC; Willis RN; Shah PM; Hennessy SA; Sawyer RG
Surg Infect (Larchmt); 2015 Dec; 16(6):684-93. PubMed ID: 26324996
[TBL] [Abstract][Full Text] [Related]
56. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use.
Mendes CA; Cordeiro JA; Burdmann EA
Ann Pharmacother; 2009 Dec; 43(12):1948-55. PubMed ID: 19887593
[TBL] [Abstract][Full Text] [Related]
57. The Influence of a Therapeutic Drug Monitoring Service on Vancomycin-Associated Nephrotoxicity.
Yang JJ; Brett J; Sordo A; Reuter SE; Stocker SL; Day RO; Roberts DM; Carland JE
J Clin Pharmacol; 2024 Jan; 64(1):19-29. PubMed ID: 37779493
[TBL] [Abstract][Full Text] [Related]
58. Is linezolid a risk factor for Gram-negative bacillus infections in intensive care unit patients? A comparative study with vancomycin.
Sterzik H; Soriano A; Mohamad AM; Martínez JA; Fernandez J; Cobos N; Morata L; Mensa J
Scand J Infect Dis; 2011 Oct; 43(10):765-70. PubMed ID: 21696252
[TBL] [Abstract][Full Text] [Related]
59. Colistin nephrotoxicity increases with age.
Balkan II; Dogan M; Durdu B; Batirel A; Hakyemez IN; Cetin B; Karabay O; Gonen I; Ozkan AS; Uzun S; Demirkol ME; Akbas S; Kacmaz AB; Aras S; Mert A; Tabak F
Scand J Infect Dis; 2014 Oct; 46(10):678-85. PubMed ID: 25073536
[TBL] [Abstract][Full Text] [Related]
60. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.
Elting LS; Rubenstein EB; Kurtin D; Rolston KV; Fangtang J; Martin CG; Raad II; Whimbey EE; Manzullo E; Bodey GP
Cancer; 1998 Dec; 83(12):2597-607. PubMed ID: 9874468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
